PROGRAM

Thursday 24.04.2014

9.00 – 18.30 - Registration

14.00-18.00 – Pre-congress course:

Zoltan Kalo (Hungary) & Dinko Vitezic (Croatia)

How pharmacoeconomics should be applied to support decisions in lower income European countries?

18.30 - 19.15 – Opening ceremony

19.15 – 20.00 - Plenary lecture

Zoltan Kalo (Hungary) – Benefits of investment into modern medicines in Central-Eastern European countries

20.30 – Welcome cocktail

Friday 25.04.2014

8.00 – 18.30 - Registration

8.30 -9.15 - Plenary lecture –

Finn Kristensen (Denmark) Current trends and future prospects of pharmacoeconomics and outcomes research - with special reference to health technology assessment

9.30 – 11.30 – Session 1 - Health economic aspect of personalized medicines
Dinko Vitezić (Croatia) - Factors influencing pharmacoeconomic assessment of new drugs in diabetes mellitus treatment

Czech Maricin (Poland) – Health economic aspects of personalized therapy in diabetic patients

Hren Rok (Slovenia) - The importance of pharmacoeconomic modeling in assessing costs of asthma treatment

Zlate Stojanovski (Macedonia) - Prophylactic use of ciprofloxacine in stem cell recipients reduce associated cost of stem cells transplantation

Vjolca Qerimi (Macedonia) – Evaluation of decision-analytic models for the treatment of multiple myeloma

11.30 – 12.00 - Coffee break (Sponsored by Alkaloid)

12.00 – 13.30 – Session 2 – HTA implementation in lower income European countries

Tomek Dominik (Slovakia) - Application of Pharmacoeconomics and HTA in Drug and Health Policies in Slovakia

Atanasievic Dragana (Serbia) – HTA implementation in Serbia

Mirjana Huić (Croatia) - HTA in Croatia: first five years

Tarik Catic (Bosnia and Herzegovina) - HTA in Bosna and Herzegovina

13.30 – 14.15 – Alkaloid satellite meeting

14.15 -15.15 – Lunch

15.15 – 16.15 – Poster session

16.30 – 17.30 – Novo Nordisk satellite meeting - Health economic properties of novel, ultra-long lasting insulin

17.30 – 19.30 - Session 3 – Improvement of generic and biosimilar drug policies

Gonzalo Calvo (Spain) - Biosimilar medicinal products: from their drug-regulation to their market-place

Borut Štrukelj (Slovenia), Biologics and biosimilars - why the principles of generics do not apply?

Vladimir Zah (Serbia) – Pricing and Reimbursement related to generic and biosimilar products in CEE region

Viktorija Erdeljic Turk (Croatia), Generic and therapeutic drug substitution

Aleksandra Grozdanova (Macedonia) - Biosimilars in Republic of Macedonia - licensing and market access
Merjem Hadzi Hamza (Macedonia) - Ethical principles promoting Good Governance in the Public Pharmaceutical sector and their impact on Health economics

Saturday 26.04.2014

8.00 – 18.30 - Registration

8.30 – 10.30 – Session 4 – Role of Health insurance on the cost-effective use of medicines

Maarten Postma (Netherland) - Pharmacoeconomic evaluation in process of introducing new vaccines in National Program of Immunization
Stephan Bevan (UK) - Work Disability Related to Musculoskeletal Disorders: Assessing the burden and identifying solutions in Slovenia and the wider EU
Maja Parnargieva-Zmejkova (Macedonia) - The role of the HIFM on effectiveness and rational use of medicines in Republic of Macedonia
Slobodanka Bolanča (Croatia): Value of innovation in pharmaceutical sector in Croatia
Rubin Zareski (Macedonia) - Pharmaceutical pricing - a continuing crisis

10.30 – 11.00 Coffee break (Sponsored by Pliva- Teva)

11.00 – 13.15 – Session 5 – Economic impact of pharmaceutical parallel trade/External reference pricing

John Yfantopoulos (Greece) - Economic impact of pharmaceutical parallel trade
Livio Garattini (Italy) - Value Based Pricing
Slobodanka Bolanča (Croatia) - TBC: Ensuring Patient Supply of Innovative Pharmaceutical Products in EU – is there any room for improvement?
Jurij Fürst (Slovenia) - The introduction of therapeutic reference pricing system in Slovenia
Guenka Petrova (Bulgaria) - The current pricing and reimbursement system for pharmaceuticals in Bulgaria
Vesna Nastova (Macedonia) - Pharmaceutical Parallel Import in the Republic of Macedonia
Biljana Dimitrova (Macedonia) - Methodology for the manner of creating prices of medicines in Republic of Macedonia
13.15 – 14.15 – FarmaBrend Nova - satellite meeting

Including new, innovative drugs on reimbursement list of NHIF- a need or financial burden

14.15 – 17.00 – Lunch/Sightseeing Ohrid

17.15 – 19.15 – Session 6 – Applied pharmacoeconomics

Aleksandar Knežević (Croatia) - Comparison of efficacy and cost of antihypertensive therapy with fixed-dose combination versus free-drug combination

Likic Robert (Croatia) - Cost effectiveness of fosfomycin use for uncomplicated urinary tract infections caused by microbial strains producing extended spectrum beta-lactamases

Sonja Genadieva Stavrik (Macedonia) - New treatment approaches in multiple myeloma patients - new drug, new price, and new quality of life. What do we gain?

Harasani Hudhra Kleida (Albania) - Potentially inappropriate prescribing identified by two different tools and health outcomes assessment

Hana Kalinić Grgorinić (Croatia) - Pharmacoeconomics of the short-term prophylaxis of the HAE attacks

Igor Kikerkov (Macedonia) – Outsourcing in pharmaceutical industry

20.00 – 23.30 – Congress dinner

Sunday 27.04.2014

09.00 – 10.30 – Session 7 – ISPOR CEE Network – regional collaboration to facilitate evidence based policy

Vlad Zah (Serbia) – Overview of ISPOR CEE Network

Ljubica Shuturkova (Macedonia) – Importance of ISPOR CEE Network for Macedonia

Guenka Petrova (Bulgaria) – ISPOR CEE Network current situation for Bulgaria

Zoran Sterjev (Macedonia) – ISPOR CEE research committee participation from R.Macedonia

Tarik Catic (Bosnia and Hercegovina) – ISPOR CEE educational activity and research projects in BiH

11.00 – 11.30 - Closing ceremony